Evidence map›Paper›PMID 35612697›Full record

ArticleJournal of neuro-oncology2022

Uptake of lipid core nanoparticles by fragments of tissues collected during cerebral tumor excision surgeries: hypotheses for use in drug targeting therapy.

Edmundo Luís Rodrigues Pereira, Danielle Cristinne Azevedo Feio, João Pojucan Lobo Tavares, Natalia Megumi Morikawa, Debora Fernandes Deus, Carolina Graziani Vital, Elaine Rufo Tavares, Raul Cavalcante Maranhão

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 62% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Edmundo Luís Rodrigues PereiraServico de Cirurgia, Nucleo de Pesquisas em Neurooncologia, Hospital Universitario Joao de Barros Barreto, Universidade Federal do Para, Belem, Para, Brazil.
Danielle Cristinne Azevedo FeioCentro Universitario Metropolitano da Amazonia - UNIFAMAZ, Belem, Para, Brazil.
João Pojucan Lobo TavaresServico de Cirurgia, Nucleo de Pesquisas em Neurooncologia, Hospital Universitario Joao de Barros Barreto, Universidade Federal do Para, Belem, Para, Brazil.
Natalia Megumi MorikawaServico de Cirurgia, Nucleo de Pesquisas em Neurooncologia, Hospital Universitario Joao de Barros Barreto, Universidade Federal do Para, Belem, Para, Brazil.
Debora Fernandes DeusInstituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil.
Carolina Graziani VitalInstituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil.
Elaine Rufo TavaresInstituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil.
Raul Cavalcante MaranhãoInstituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil. ramarans@usp.br.
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRUniversidade Federal do Pará · BRFaculdade Metropolitana de Manaus

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 431290/2016-4Fundação de Amparo à Pesquisa do Estado de São Paulo, Brazil 2014/03742-0
6 · The paper itself

Abstract

purposeMalignant cerebral tumors have poor prognosis and the blood-brain barrier is a major hindrance for most drugs to reach those tumors. Lipid nanoparticles (LDE) that bind to lipoprotein receptors may carry anticancer drugs and penetrate the cells through those receptors that are overexpressed in gliomas. The aim was to investigate the in vivo uptake of LDE by human cerebral tumors.

methodsTwelve consecutive patients (4 with glioblastomas, 1 meduloblastoma, 1 primary lymphoma, 2 with non-cerebral metastases and 4 with benign tumors) scheduled for tumor excision surgery were injected intravenously, 12 h before surgery, with LDE labeled

resultsTumor LDE uptake (range: 10-283 d.p.m./g of tissue) was not lower than that of normal tissues (range: 20-263 d.p.m./g). Malignant tumor uptake was threefold greater than benign tumor uptake (140 ± 93 vs 46 ± 18 d.p.m./g, p < 0.05). Results show that LDE can concentrate in brain malignant tumors and may be used to carry drugs directed against those tumors.

conclusionAs LDE was previously shown to markedly decrease drug toxicity this new therapeutic strategy should be tested in future trials.

Indexed as

NanoparticlesDrug Delivery SystemsEmulsionsHumansLiposomesEmulsionsLipid NanoparticlesLiposomesBlood–brain barrierGlioma treatmentLDL-receptor and cancerNanoemulsionsSolid lipid nanoparticles

Identifiers

PMID35612697
OpenAlexW4281485721

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.